These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 19317316)
1. [American Heart Association conference 2008. The JUPITER trial, the approval of prasugrel, the (aging) heart of obese adolescents]. Schaerlig E Rev Med Suisse; 2009 Feb; 5(192):482-5. PubMed ID: 19317316 [No Abstract] [Full Text] [Related]
2. Prasugrel (Effient) vs. clopidogrel (Plavix). Med Lett Drugs Ther; 2009 Sep; 51(1320):69-70. PubMed ID: 19738549 [TBL] [Abstract][Full Text] [Related]
3. [Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007]. Schaerlig E Rev Med Suisse; 2008 Feb; 4(144):434-5. PubMed ID: 18320775 [No Abstract] [Full Text] [Related]
4. By Jove! What is a clinician to make of JUPITER? Kaul S; Morrissey RP; Diamond GA Arch Intern Med; 2010 Jun; 170(12):1073-7. PubMed ID: 20585074 [No Abstract] [Full Text] [Related]
5. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380 [TBL] [Abstract][Full Text] [Related]
6. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us? Krane V; Wanner C Am J Kidney Dis; 2005 Mar; 45(3):607-9. PubMed ID: 15754285 [No Abstract] [Full Text] [Related]
7. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Wiviott SD; Braunwald E; Murphy SA; Antman EM; Am J Cardiol; 2008 May; 101(9):1367-70. PubMed ID: 18435974 [No Abstract] [Full Text] [Related]
8. Mortality in the TRITON trial: update from the FDA prasugrel action package. Serebruany VL Am J Cardiol; 2010 May; 105(9):1356-7. PubMed ID: 20403493 [No Abstract] [Full Text] [Related]
9. Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?). Serebruany VL Am J Cardiol; 2008 May; 101(9):1364-6. PubMed ID: 18435973 [No Abstract] [Full Text] [Related]
10. Molecule of the month. Pasugrel. Drug News Perspect; 2006 Oct; 19(8):490. PubMed ID: 17160150 [No Abstract] [Full Text] [Related]
11. Prasugrel, a third generation thienopyridine and potent platelet inhibitor. Gurbel PA; Tantry US Curr Opin Investig Drugs; 2008 Mar; 9(3):324-36. PubMed ID: 18311669 [TBL] [Abstract][Full Text] [Related]
16. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Baker WL; White CM Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817 [TBL] [Abstract][Full Text] [Related]
18. Study stirs debate about statin use in those without high cholesterol. Mayo Clin Womens Healthsource; 2009 Apr; 13(4):3. PubMed ID: 19255535 [No Abstract] [Full Text] [Related]
19. Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill? Wienbergen H; Senges J; Gitt AK Diabetes Care; 2008 Feb; 31 Suppl 2():S222-5. PubMed ID: 18227489 [No Abstract] [Full Text] [Related]
20. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist]. Alban S Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350 [No Abstract] [Full Text] [Related] [Next] [New Search]